Sight Sciences Continues To Expect Double-Digit Surgical Glaucoma Revenue Growth In H2
Portfolio Pulse from Benzinga Newsdesk
Sight Sciences anticipates double-digit growth in surgical glaucoma revenue in the second half of 2024. However, the company expects a decrease in dry eye revenue due to a price increase effective October 1, 2024, which is likely to negatively impact cash-pay procedure volumes before a projected return to growth in 2025.
August 01, 2024 | 9:10 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sight Sciences expects double-digit growth in surgical glaucoma revenue in H2 2024 but anticipates a decrease in dry eye revenue due to a price increase effective October 1, 2024. The company expects this to negatively impact cash-pay procedure volumes before a return to growth in 2025.
The anticipated double-digit growth in surgical glaucoma revenue is positive, but the expected decrease in dry eye revenue due to a price increase could offset this in the short term. The market may react neutrally as the negative impact on dry eye revenue is expected to be temporary, with growth resuming in 2025.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100